Choosing the Right Macrolide Antibiotic. A Guide to Selection

Overview

Journal Drugs

Specialty Pharmacology

Date 1997 Mar 1

PMID 9074839

Citations 6

Authors

L Charles

J Segreti

Affiliations

Soon will be listed here.

Abstract

Macrolide antibiotics have proven to be valuable alternatives to penicillins and cephalosporins for the treatment of a number of infections. Currently, a number of macrolides are available. When choosing a particular macrolide, the types of organisms causing the infection, the tolerability of the drug, convenience of dosing and possible drug interactions all must be taken into account. Erythromycin, azithromycin and clarithromycin are equally effective against most gram-positive organisms. However, clarithromycin and azithromycin have much better activity against Haemophilus influenza and Moraxella catarrhalis. Thus, these 2 drugs are better choices for the treatment of community-acquired pneumonia. However, the low serum concentrations of azithromycin may be a problem in patients with bacteraemia associated with with community-acquired pneumonia. Clarithromycin appears to be effective for the treatment and prophylaxis of Mycobacterium avium complex (MAC) in patients with AIDS, while azithromycin appears to be effective for prophylaxis. Treatment of MAC with azithromycin is currently undergoing study. Although clarithromycin is the macrolide of choice for the treatment of Helicobacter pylori, azithromycin is the preferred macrolide for the treatment of Chlamydia trachomatis infections. The major factor limiting the use of azithromycin and clarithromycin has been their cost. However, these drugs may be cost effective if compliance is improved due to better tolerability and more convenient dosing regimens.

Citing Articles

[Guidelines for the management of community pneumonia in adult who needs hospitalization].

Alvarez-Rocha L, Alos J, Blanquer J, Alvarez-Lerma F, Garau J, Guerrero A Med Intensiva. 2024; 29(1):21-62.

PMID: 38620135 PMC: 7131443. DOI: 10.1016/S0210-5691(05)74199-1.

Breaking boundaries: the advancements in transdermal delivery of antibiotics.

Zaid Alkilani A, Hamed R, Musleh B, Sharaire Z Drug Deliv. 2024; 31(1):2304251.

PMID: 38241087 PMC: 10802811. DOI: 10.1080/10717544.2024.2304251.

Erythromycin decreases the time and improves the quality of EGD in patients with acute upper GI bleeding.

Ehsani Ardakani M, Zare E, Basiri M, Mohaghegh Shalmani H Gastroenterol Hepatol Bed Bench. 2014; 6(4):195-201.

PMID: 24834272 PMC: 4017518.

A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days.

Crokaert F, Hubloux A, Cauchie P Clin Drug Investig. 2008; 16(2):161-6.

PMID: 18370534 DOI: 10.2165/00044011-199816020-00009.

Review of macrolides and ketolides: focus on respiratory tract infections.

Zhanel G, Dueck M, Hoban D, Vercaigne L, Embil J, Gin A Drugs. 2001; 61(4):443-98.

PMID: 11324679 DOI: 10.2165/00003495-200161040-00003.

References

Steingrimsson O, Olafsson J, THORARINSSON H, Ryan R, Johnson R, Tilton R . Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother. 1990; 25 Suppl A:109-14. DOI: 10.1093/jac/25.suppl_a.109. View

Fernandes P, Bailer R, Swanson R, Hanson C, McDonald E, Ramer N . In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986; 30(6):865-73. PMC: 180609. DOI: 10.1128/AAC.30.6.865. View

Inderlied C, Kolonoski P, Wu M, Young L . In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis. 1989; 159(5):994-7. DOI: 10.1093/infdis/159.5.994. View

OBRIEN B, Goeree R, Mohamed A, Hunt R . Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med. 1995; 155(18):1958-64. View

Bonnet M, Van der Auwera P . In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob Agents Chemother. 1992; 36(6):1302-9. PMC: 190336. DOI: 10.1128/AAC.36.6.1302. View

Pukander J, Jero J, Kaprio E, Sorri M . Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J. 1993; 12(12 Suppl 3):S118-21. DOI: 10.1097/00006454-199312003-00005. View

Hardy D, SWANSON R, Rode R, Marsh K, Shipkowitz N, Clement J . Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990; 34(7):1407-13. PMC: 175991. DOI: 10.1128/AAC.34.7.1407. View

Vakil N, Fennerty B . The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med. 1996; 100(5A):60S-63S; discussion 63S-64S. DOI: 10.1016/s0002-9343(96)80230-0. View

Hoepelman A, Sips A, van Helmond J, van Barneveld P, Neve A, Zwinkels M . A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. J Antimicrob Chemother. 1993; 31 Suppl E:147-52. DOI: 10.1093/jac/31.suppl_e.147. View

10.

Kirst H, Sides G . New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother. 1989; 33(9):1413-8. PMC: 172675. DOI: 10.1128/AAC.33.9.1413. View

11.

Amacher D, Schomaker S, Retsema J . Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother. 1991; 35(6):1186-90. PMC: 284308. DOI: 10.1128/AAC.35.6.1186. View

12.

Glupczynski Y, Burette A . Failure of azythromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am J Gastroenterol. 1990; 85(1):98-9. View

13.

Strle F, Ruzic E, Cimperman J . Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrob Chemother. 1992; 30(4):543-50. DOI: 10.1093/jac/30.4.543. View

14.

Piscitelli S, Danziger L, Rodvold K . Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992; 11(2):137-52. View

15.

Edelstein P, Edelstein M . In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother. 1991; 35(1):180-1. PMC: 244963. DOI: 10.1128/AAC.35.1.180. View

16.

Alder J, Mitten M, Jarvis K, Gupta P, Clement J . Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother. 1993; 37(6):1329-33. PMC: 187961. DOI: 10.1128/AAC.37.6.1329. View

17.

Segreti J, Kessler H, Kapell K, Trenholme G . In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. Antimicrob Agents Chemother. 1987; 31(1):100-1. PMC: 174660. DOI: 10.1128/AAC.31.1.100. View

18.

Gladue R, Snider M . Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother. 1990; 34(6):1056-60. PMC: 171758. DOI: 10.1128/AAC.34.6.1056. View

19.

Nuovo J, Melnikow J, Paliescheskey M, King J, Mowers R . Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. J Am Board Fam Pract. 1995; 8(1):7-16. View

20.

Pierce M, Crampton S, Henry D, Heifets L, Lamarca A, Montecalvo M . A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996; 335(6):384-91. DOI: 10.1056/NEJM199608083350603. View